Pregabalin Capsule
Product Images NDC 71610-871

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-871). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0871 30)

Label for Pregabalin 100 mg capsules, containing 30 capsules. The label includes storage instructions to keep between 20-25 degrees Celsius and warnings about habit formation. Manufactured by Aurobindo Pharma USA, Inc. and packaged by Aphena Pharma Solutions - Tennessee, LLC.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Pregabalin Equation (Pregabalin Equ)

An illustration showing the formula for calculating creatinine clearance (CLCr). The formula accounts for age, weight, serum creatinine level, and includes a multiplier of 0.85 for female patients.*

FDA Label Image

Figure 1: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Dpn 1 (Pregabalin Fig1)

A line graph titled 'Patients Achieving Various Levels of Improvement in Pain Intensity – Study DPN 1' showing percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, Pregabalin 25 mg three times a day, and placebo, with percentage improvements increasing along the x-axis and percent of patients improved on the y-axis.*

FDA Label Image

Figure 10 (Pregabalin Fig10)

Kaplan-Meier analysis chart titled 'Time to Loss of Therapeutic Response, Fibromyalgia Study F2,' comparing Pregabalin and placebo groups. The vertical axis shows the estimated percentage of subjects without loss of therapeutic response from 0% to 100%, and the horizontal axis shows days from 0 to 180. The chart has two lines: a solid line for Pregabalin and a dashed line for placebo, indicating the time course of therapeutic response retention in subjects.*

FDA Label Image

Figure 11 (Pregabalin Fig11)

A line graph depicting the percent of subjects improved over baseline to Week 12 based on BOCF (Baseline Observation Carried Forward). The Y-axis shows percent of subjects improved from 0 to 100%, and the X-axis shows percent improvement from baseline to Week 12 from 0 to 100%. Two lines are shown: one solid line representing Pregabalin and one dotted line representing Placebo, with the Pregabalin line consistently higher across percent improvement values.*

FDA Label Image

Figure 12 (Pregabalin Fig12)

A line graph comparing the percentage of subjects improved over baseline to week 16 measured by BOCF, contrasting Pregabalin treatment with placebo. The x-axis shows percent improvement from 0 to 100, and the y-axis shows the percent of subjects improved from 0 to 100%. The graph includes two lines: a solid line for Pregabalin and a dashed line for placebo, illustrating higher improvement rates with Pregabalin at most points.*

FDA Label Image

Figure 2: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study (Pregabalin Fig2)

A line graph comparing percent improvement in pain from baseline with the percent of patients improved in the Study DPN 2. It shows two lines: one for Pregabalin 100 mg three times a day and one for placebo, indicating patient outcomes at various levels of pain improvement.*

FDA Label Image

Figure 3: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Phn 1 (Pregabalin Fig3)

This line graph titled 'Patients Achieving Various Levels of Improvement in Pain Intensity — Study PHN 1' shows the percent of patients improved at different levels of percent improvement in pain from baseline. It compares Pregabalin doses of 300 mg, 150 mg, and 75 mg taken twice daily, and a placebo. The x-axis represents percent improvement in pain from baseline (0 to 100%), and the y-axis represents the percent of patients improved (0 to 100%). Lines illustrate patient improvement trends for each dose and placebo.*

FDA Label Image

Figure 4: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Phn 2 (Pregabalin Fig4)

A line graph titled 'Patients Achieving Various Levels of Improvement in Pain Intensity – Study PHN 2' showing percent of patients improved versus percent improvement in pain from baseline. It compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo, with the 200 mg group showing higher percent improvement rates.*

FDA Label Image

Figure 5: Patients Achieving Various Levels Of Improvement In Pain Intensity – Study Phn 3 (Pregabalin Fig5)

A line graph titled 'Patients Achieving Various Levels of Improvement in Pain Intensity – Study PHN 3' showing percent of patients improved on the y-axis and percent improvement in pain from baseline on the x-axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and placebo. The graph illustrates patient improvement percentages across varying pain improvement thresholds.*

FDA Label Image

Figure6 (Pregabalin Fig6)

Bar chart titled 'Study E1' and 'Study E3' showing responder rates (%) for Pregabalin oral capsules versus placebo. Study E1 compares placebo and four Pregabalin doses (50, 150, 300, 600 mg/day BID). Study E3 compares placebo, 600 mg/day BID, and 600 mg/day TID. The chart illustrates increasing responder rates with higher doses compared to placebo in both studies.*

FDA Label Image

Figure7 (Pregabalin Fig7)

A line graph showing seizure reduction as median percent change from baseline versus dose in mg/day. Four studies are represented with different markers: Study E1 BID (circle), Study E2 TID (square), Study E3 BID (triangle), and Study E3 TID (inverted triangle). Seizure reduction increases with higher doses, with significant p-values indicated at multiple dose levels.*

FDA Label Image

Figure 8 (Pregabalin Fig8)

A vertical bar chart displaying responder rates (%) for three groups: placebo, 2.5 mg/kg/day, and 10 mg/kg/day. The responder rates increase from left to right, with the placebo group around 22.6%, the 2.5 mg/kg/day group about 29.1%, and the 10 mg/kg/day group approximately 40.6%. The sample sizes (N) for each group are shown below the x-axis labels.*

FDA Label Image

Figure 9 (Pregabalin Fig9)

A line graph titled 'Patients Achieving Various Levels of Improvement in Pain Intensity – Fibromyalgia Study F1' showing percent of patients improved on the y-axis and percent improvement in pain from baseline on the x-axis. It compares four groups: Pregabalin 600 mg daily dose, 450 mg daily dose, 300 mg daily dose, and placebo, with separate lines for each dose and placebo.*

FDA Label Image

Chemical Structure (Pregabalin Str)

Chemical structure of pregabalin, showing a cyclohexane ring with attached carboxylic acid (CO2H) and amino (NH2) functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.